

Q2 2021 Financial Results

September 7, 2021

Andrin Oswald, M.D. - CEO René Just - CFO



Safe Harbor Statement

This presentation has been prepared by Centogene N.V. (The "Company"), is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities, nor shall there be any sale of any securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of this presentation unless stated otherwise, and neither the delivery of this presentation at any time, nor any sale of securities, shall under any circumstances create an implication that the information that subsequently becomes available or changes occurring after the date hereof.

This presentation contains "forward-looking statements" within the meaning of the U.S. Federal securities laws, Statements contained, "herein that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," continues," "expect," "can," "may," are generally intended to identify forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause the company's actual results, performance, or achievements to be materially different from any future results, performance, or achievements. Such risks and uncertainties include, among others, negative worldwide economic conditions and ongoing instability and volatility in the worldwide financial markets, the effects of the COVID-19 pandemic on our business and results of operations, possible changes in current and proposed legislation, regulations and governmental policies, pressures from increasing competition and consolidation in our industry, the expense and uncertainty of regulatory approval, including from the U.S. Food and Drug Administration, our reliance on third parties and collaboration partners, including our ability to manage growth and enter into new client ractions. For further information on the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the Company's business in general, see the Company's risk factors set forth in the Company's form 20-F filed on April 15, 2021 with the Securities and Exchange Commission (he "SEC") and subsequent filings with the SEC. Any forward-looking statements contained in this presentation speak only as of the date hereof, and the company's pecifically disclaims any obligation to update any forward-looking statements worldwide to new information, future events or other worldwide expenses on the set of a conservence on the set of a conservence on the resense and uncertainty of regulatory approval, including

Certain information contained in this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and the Company's own internal estimates and research. While the Company believes these third-party sources to be reliable as of the date of this presentation, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, all of the market data included in this presentation involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. Finally, while the Company believes its own internal research is reliable, such research has not been verified by any independent source.


Today's Speakers



Andrin Oswald, M.D. Chief Executive Officer



René Just Chief Financial Officer Agenda



Q2 Performance Reflects Recovery in Core Business

Strong financial performance

- Strong revenue growth year-over-year for Q2 driven by strong Covid-19 testing and Clinical Diagnostics revenues
- Core business demonstrating recovery to pre-pandemic with revenue increase of 25%
- Strong segment **adjusted EBITDA** multiple quarters in a row
- Expanded Bio/Databank with ~24k new patients; steady increase towards goal of 1 million patients
- Offering the **broadest diagnostic testing portfolio** for rare diseases, covering over 19,000 genes using over 10,000 different tests.
- Expansion on Pharma partnership contracts continues; revenues lumpy in part due to continued COVID resource diversions
- 53 active collaborations; H1 2021 signed contract value exceeds FY 2020 signed contract value


Diagnostics

Pharma

Strong Revenue

Q2 Revenue¹

(€ Millions)



Financial Highlights

- Revenues more than quadrupled in Q2 2021 compared to Q2 2020, driven by growth from COVID-19 testing and the Diagnostics segment
- Diagnostics revenues (excl. COVID) increased 82% compared to Q2 2020
- Pharma revenues decreased YoY from €3.9 million in Q2 2020 to € 2.8 million in Q2 2021
- Commercial COVID-19 testing contributed €42.3 million in revenues in Q2 2021, up from €2.1 million in Q2 2020


Continuing to Expand our Knowledge Repository

Sample Order Intake Core Business¹

(Number in Thousands, rounded)

Patients in Repository²

(Number in Thousands, rounded)




¹ Reflects the number of test requests for diagnostic analysis for individuals from the core business, i.e. excluding COVID-19 related tests, during the period. Multiple orders may be associated with one individual; an order may relate to analysis of a new sample or to additional (re-)analysis of an existing sample.

² Number of patients in repository indicative of registered individuals in CENTOGENE (laboratory) information systems related to the core business, i.e., Clinical Diagnostics and Pharma segment.

R&D at CENTOGENE






Our Growing Bio/Databank Enables Key Use Cases With Data Breadth & Multiomic Depth



Establishing Relevant Datasets With Multiomics for Orphan Drug Discovery and Development




Leading Data-Driven Insights Creator in Rare Diseases


Peer Group of Data-driven Insights Companies

			TEMPUS	Ŷ	SEMA4	insitro	Q	flatiron
X	Focus on rare diseases	\checkmark	X	X		\checkmark		×
	Databank	\checkmark		\checkmark		\checkmark		\checkmark
	Biosamples	\checkmark				X		X
	Proprietary data value chain	\checkmark		\checkmark		\checkmark		\checkmark
Contraction of the second seco	Geographical diversity	\checkmark	X		X	X	X	X
GATTCGA ACGTTCG GGACACT	Commercial multiomic products		X	X	X	X		X

Agenda




Q2 2021 and H1 2021 Segment Revenue



Q2 2021 Segment Adjusted EBITDA

Segment Adjusted EBITDA

(€ Thousands)





Financial Highlights

- Total segment adjusted EBITDA grew to €7.5 million in Q2 2021 compared to €1.0 million in Q1 2021
- Positive segment adjusted EBITDA, driven by COVID-19 testing revenues; continuing to invest in the rare disease core business


Pharma Collaborations and H1 2021 Revenue Breakdown

(€ Millions) 8.5 0.2 -25% ∽ 6.4 0.2 4.8 4.2 3.5 2.0 H1 2020 H1 2021 Total Drug Discovery R&D Collaborations Patient Identification (on-market products) Clinical Trial Support May include rounding differences.

Revenue by Deal Type

Pharma Highlights


- H1 2021 total 53 active collaborations (12 new, 3 extended and 25 completed) vs. H1 2020 63 active collaborations
- Revenue from new/extended collaborations in H1 2021 €2.1 million
- Signed 7 new deals covering the pharma service universe in Q2 2021 compared to 5 new deals in Q1 2021
- Signed contract value higher in H1 2021 vs FY 2020



- Clinical Trial Support
- Patient Identification
- Drug Discovery R&D Collaborations

Chart depicts breakdown of number of active collaborations by type per June 30, 2021.

Q2 Clinical Diagnostics Revenue Breakdown



Diagnostic Highlights

- Revenues from our Diagnostics segment were €6.7 million in Q2 2021
- Diagnostics revenues (excl. COVID) increased 82% compared to €3.7 million in Q2 2020
- The increase in revenues was primarily related to an increase in test requests for WES and WGS

Income Statement¹

	For the <u>thre</u> ended June in € millions	e 30	For the <u>six</u> ended June in € millions	e 30
	2020	2021	2020	2021
Revenue	9.7	51.9	21.8	116.8
Cost of sales	6.8	43.8	13.8	95.7
Gross profit	2.9	8.1	8.0	21.1
Research and development expenses	3.1	4.1	5.8	8.4
General administrative expenses	7.8	10.5	15.7	22.1
Selling expenses	2.4	1.9	4.7	3.9
Impairment of financial assets	0.5	0.6	1.7	0.7
Other operating income	0.8	1.3	1.7	1.6
Other operating expenses	0.0	0.0	0.1	0.0
Operating loss	(10.1)	(7.7)	(18.3)	(12.3)

		For the six months ended June 30, 2020 € Millions	For the six months ended June 30, 2021 € Millions	Period-over-period change € Millions
	Cash flow from/(used in) operating activities	(14.6)	(7.8)	6.8
Key Items	Cash flow from/(used in) investing activities	(6.6)	(4.8)	1.8
	Cash flow from financing activities	(2.4)	(0.8)	1.7
		As of March 31, 2021 € Millions	As of June 30, 2021 € Millions	Period-over-period change € Millions
	Cash & cash equivalents	45.2	34.8	(10.4)
Key Items	Debt outstanding ²	(24.4)	(23.6)	0.8

11.2

20.8


¹Selected information

² Debt outstanding includes non-current loans, non-current lease liabilities, current loans and current lease liabilities. May include rounding differences.

Net cash/ (net debt)

(9.6)

Agenda



Summary & Outlook

	 Strong top line revenue supported by commercial COVID-19 testing 				
02 and U1 200	 Core business recovery with >25% growth in Q2 2021, 82% growth in Diagnostics vs Q2 2020 				
Q2 and H1 202 Summary	 Addition of 5 new members to management team; most recently Patrice Denèfle, Chief Scientific Officer 				
	 Reached ~ 650,000 patients in Bio/Databank; continuously improving our rare disease-centric insights 				
	 FY 2021 revenue now expected to surpass vs. FY 2020 with core business segments continuing solid business growth in H2 2021 				

FY and H2 2021 Outlook

- Non-core business of commercial COVID-19 testing difficult to predict but expected to slow down in H2 2021 due to increased vaccination rates
- Continue to **make strategic investments** into core business segments to enhance leading position in the rare disease space and generate long-term value



Thank You for Joining

Q2 2021 Financial Results



	For the three months ended June 30		For the six months ended June 30	
	2020	2021	2020	2021
Revenue	9,719	51,871	21,824	116,831
Cost of sales	6,815	43,760	13,833	95,707
Gross profit	2,904	8,111	7,991	21,124
Research and development expenses	3,119	4,053	5,810	8,388
General administrative expenses	7,767	10,494	15,665	22,090
Selling expenses	2,386	1,942	4,712	3,891
Impairment of financial assets	500	580	1,674	675
Other operating income	801	1,276	1,746	1,642
Other operating expenses	37	2	138	36
Operating loss	(10,104)	(7,684)	(18,262)	(12,314)
Interest and similar income	13	_	13	_
Interest and similar expense	269	212	718	471
Financial costs, net	(256)	(212)	(705)	(471)
Loss before taxes	(10,360)	(7,896)	(18,967)	(12,785)
Income tax expenses	—	124	129	124
Loss for the period	(10,360)	(8,020)	(19,096)	(12,909)
Other comprehensive income/ (loss), all attributable to equity			· · · ·	
holders of the parent	(6)	(191)	70	(70)
Total comprehensive loss	(10,366)	(8,211)	(19,026)	(12,979)
Attributable to:				
Equity holders of the parent	(10,364)	(8,222)	(18,963)	(13,025)
Non-controlling interests	(2)	11	(63)	46
	(10,366)	(8,211)	(19,026)	(12,979)
Loss per share - Basic and diluted (in EUR)	(0.52)	(0.37)	(0.95)	(0.58)

Balance Sheet			Equity and liabilities	Dec 31, 2020	June 30, 2021
			Equity		
			Issued capital	2,654	2,693
_			Capital reserve	125,916	130,153
Assets	Dec 31, 2020	June 30, 2021	Retained earnings and other reserves	(62,888)	(75,913)
Non-current assets			Non-controlling interests	95	141
Intangible assets	12,407	12,179		65,777	57,074
-			Non-current liabilities		
Property, plant and equipment	16,590	16,411	Non-current loans	401	200
Right-of-use assets	22,120	20,558	Lease liabilities	17,677	16,209
Other assets	1,967	3,023	Deferred tax liabilities	207	246
	52.004	50 171	Government grants	8,950	8,640
	53,084	52,171		27,235	25,295
Current assets			Current liabilities		
Inventories	11,405	9,281	Government grants	1,342	1,352
Trade receivables and contract assets	29,199	18,490	Current loans	2,492	3,883
			Lease liabilities	3,528	3,299
Other assets	8,286	6,064	Trade payables	31,736	14,014
Cash and cash equivalents	48,156	34,780	Liabilities from income taxes	58	143
	97,046	68,615	Other liabilities	17,962	15,726
			-	57,118	38,417
	150,130	120,786	_	150,130	120,786

		For the six months ended June 30 2020	2021
Cash Flow	Operating activities Loss before taxes	(18,967)	(12,785)
	Adjustments to reconcile loss to cash flow from operating activities Amortization and depreciation	4,432	6,670
	Interest income	(13)	471
	Interest expense Expected credit loss allowances on trade receivables and contract assets	718 1,674	471 675
	Share-based payment expenses	1,393	4,276
	Tax expense	129	124
	Other non-cash items	(686)	126
	Changes in operating assets and liabilities		
	Inventories	(6,252)	2,124
	Trade receivables and contract assets	(64) 269	10,034
	Other assets Trade payables	209	328 (17,722)
	Other liabilities	2,457	(2,151)
	Cash flow used in operating activities	(14,636)	(7,830)
	Investing activities		
	Cash paid for investments in intangible assets	(3,965)	(2,089)
	Cash paid for investments in property, plant and equipment	(3,072)	(2,696)
	Grants received for investment in property, plant and equipment	390	—
	Interest received	13	—
	Cash flow used in investing activities	(6,634)	(4,785)
	Financing activities		
	Cash paid for acquisition of non-wholly owned subsidiary	(75)	_
	Cash received from loans	928	1,769
	Cash repayments of loans Cash repayments of lease liabilities	(1,260) (1,619)	(185) (2,263)
	Interest paid	(399)	(2,203) (82)
	Cash flow from used in financing activities	(2,425)	(761)
	Changes in cash and cash equivalents	(23,695)	(13,376)
	Cash and cash equivalents at the beginning of the period	41,095	48,156
	Cash and cash equivalents at the end of the period	17,400	34,780